Teprotumumab Proves Efficacious for Proptosis in Thyroid Eye Disease

Researchers reviewed teprotumumab in patients with TED who had lower clinical activity scores than those evaluated in 2 randomized trials.

Related Keywords

Germany ,United States ,Washington ,Berlin ,American ,Francis Sedlakm Teprotumumab ,Jean Slutsky ,Drug Administration ,American Academy Of Ophthalmology ,Research In Multiple Sclerosis ,Outcomes Research Institute ,Elsevier ,European Committee For Treatment ,European Committee ,Multiple Sclerosis ,Neurology Advisor ,American Academy ,Patient Centered Outcomes Research Institute ,Med Central ,